Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of venetoclax resistance and solutions

12 Oct 2022

Abstract excerpt

The BCL-2 inhibitor venetoclax is currently approved for treatment of hematologic diseases and is widely used either as monotherapy or in combination strategies. It has produced promising results in the treatment of refractory or relapsed (R/R) and aged malignant hematologic diseases. However, with clinical use, resistance to venetoclax has emerged. We review the mechanism of reduced dependence on BCL-2 mediated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cell death mechanisms and regulation
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36313732
DOI: 10.3389/fonc.2022.1005659

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of venetoclax resistance and solutionsPMID 36313732Read ↗

Progress in understanding the mechanisms of resistance to BCL-2 inhibitorsSemantic proximity Read ↗

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignanciesSemantic proximity Read ↗

Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistanceSemantic proximity Read ↗

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?Semantic proximity Read ↗

Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Venetoclax resistance: mechanistic insights and future strategiesSemantic proximity Read ↗

Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target ResistanceSemantic proximity Read ↗

Targeting Bcl-2 Proteins in Acute Myeloid LeukemiaSemantic proximity Read ↗

AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens.Semantic proximity Read ↗

Venetoclax Resistance in Acute Myeloid LeukemiaSemantic proximity Read ↗

Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell LymphomasSemantic proximity Read ↗

BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin LymphomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.